"C-Peptide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The middle segment of proinsulin that is between the N-terminal B-chain and the C-terminal A-chain. It is a pancreatic peptide of about 31 residues, depending on the species. Upon proteolytic cleavage of proinsulin, equimolar INSULIN and C-peptide are released. C-peptide immunoassay has been used to assess pancreatic beta cell function in diabetic patients with circulating insulin antibodies or exogenous insulin. Half-life of C-peptide is 30 min, almost 8 times that of insulin.
| Descriptor ID |
D002096
|
| MeSH Number(s) |
D06.472.699.587.200.500.250 D12.644.548.586.200.500.250
|
| Concept/Terms |
C-Peptide- C-Peptide
- C Peptide
- Connecting Peptide
- Proinsulin C-Peptide
- Proinsulin C Peptide
- C-Peptide, Proinsulin
- C Peptide, Proinsulin
|
Below are MeSH descriptors whose meaning is more general than "C-Peptide".
Below are MeSH descriptors whose meaning is more specific than "C-Peptide".
This graph shows the total number of publications written about "C-Peptide" by people in this website by year, and whether "C-Peptide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1995 | 0 | 2 | 2 |
| 1996 | 0 | 2 | 2 |
| 1997 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 3 | 3 |
| 2003 | 1 | 0 | 1 |
| 2004 | 0 | 3 | 3 |
| 2005 | 0 | 4 | 4 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 3 | 3 |
| 2008 | 0 | 5 | 5 |
| 2009 | 0 | 4 | 4 |
| 2010 | 0 | 1 | 1 |
| 2012 | 0 | 5 | 5 |
| 2013 | 2 | 2 | 4 |
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 2 | 2 |
| 2016 | 0 | 5 | 5 |
| 2017 | 0 | 2 | 2 |
| 2018 | 0 | 1 | 1 |
| 2019 | 2 | 0 | 2 |
| 2020 | 1 | 4 | 5 |
| 2021 | 1 | 3 | 4 |
| 2022 | 0 | 4 | 4 |
| 2023 | 0 | 2 | 2 |
| 2024 | 2 | 2 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "C-Peptide" by people in Profiles.
-
Clinical Prediction Models Combining Routine Clinical Measures Have High Accuracy in Identifying Youth-Onset Type 2 Diabetes Defined by Maintained Endogenous Insulin Secretion: The SEARCH for Diabetes in Youth Study. Diabetes Care. 2024 Dec 01; 47(12):2110-2119.
-
Comparisons of Metabolic Measures to Predict T1D vs Detect a Preventive Treatment Effect in High-Risk Individuals. J Clin Endocrinol Metab. 2024 Jul 12; 109(8):2116-2123.
-
Early Metabolic Endpoints Identify Persistent Treatment Efficacy in Recent-Onset Type 1 Diabetes Immunotherapy Trials. Diabetes Care. 2024 Jun 01; 47(6):1048-1055.
-
Inaccurate diagnosis of diabetes type in youth: prevalence, characteristics, and implications. Sci Rep. 2024 04 17; 14(1):8876.
-
Initial Insights into the Genetic Variation Associated with Metformin Treatment Failure in Youth with Type 2 Diabetes. Pediatr Diabetes. 2023; 2023.
-
Phenotypes Associated With Zones Defined by Area Under the Curve Glucose and C-peptide in a Population With Islet Autoantibodies. Diabetes Care. 2023 05 01; 46(5):1098-1105.
-
Persistence of ?-Cell Responsiveness for Over Two Years in Autoantibody-Positive Children With Marked Metabolic Impairment at Screening. Diabetes Care. 2022 12 01; 45(12):2982-2990.
-
The Transition From a Compensatory Increase to a Decrease in C-peptide During the Progression to Type 1 Diabetes and Its Relation to Risk. Diabetes Care. 2022 10 01; 45(10):2264-2270.
-
Optimizing maturity-onset diabetes of the young detection in a pediatric diabetes population. Pediatr Diabetes. 2022 06; 23(4):447-456.
-
Index60 Identifies Individuals at Appreciable Risk for Stage 3 Among an Autoantibody-Positive Population With Normal 2-Hour Glucose Levels: Implications for Current Staging Criteria of Type 1 Diabetes. Diabetes Care. 2022 02 01; 45(2):311-318.